NCT01925131 - S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2014

Primary Completion Date

January 1, 2022

Study Completion Date

January 1, 2023

Conditions

Acute Leukemias of Ambiguous LineageB-cell Adult Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Burkitt Lymphoma

Interventions

DRUG

cyclophosphamide

Given IV

DRUG

vincristine sulfate

Given IV

DRUG

prednisone

Given PO

BIOLOGICAL

inotuzumab ozogamicin

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (5)

14642

University of Rochester, Rochester

44195

Cleveland Clinic Foundation, Cleveland

77030

Ben Taub General Hospital, Houston

91010

City of Hope Comprehensive Cancer Center, Duarte

94304

Stanford Cancer Institute Palo Alto, Palo Alto

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

SWOG Cancer Research Network

NETWORK